Gemma Salvadó

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon et al. · JAMA Neurology · 2021 · 566 citations · Full text

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s <i>continuum</i> when only subtle changes in Aβ pathology are detected

Marc Suárez‐Calvet, Thomas K. Karikari, Nicholas J. Ashton et al. · EMBO Molecular Medicine · 2020 · 392 citations · Full text

Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

Nicolas R Barthélemy, Gemma Salvadó, Suzanne E. Schindler et al. · Nature Medicine · 2024 · 354 citations · Full text

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Marta Milà‐Alomà, Nicholas J. Ashton, Mahnaz Shekari et al. · Nature Medicine · 2022 · 341 citations · Full text

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

Niklas Mattsson, Gemma Salvadó, Nicholas J. Ashton et al. · JAMA Neurology · 2023 · 260 citations · Full text